AXB

60.3

+0.84%↑

JPM

294.13

+1.77%↑

BAC

45.83

+0.48%↑

WFC

77.54

-0.32%↓

MS

141.35

+1.6%↑

AXB

60.3

+0.84%↑

JPM

294.13

+1.77%↑

BAC

45.83

+0.48%↑

WFC

77.54

-0.32%↓

MS

141.35

+1.6%↑

AXB

60.3

+0.84%↑

JPM

294.13

+1.77%↑

BAC

45.83

+0.48%↑

WFC

77.54

-0.32%↓

MS

141.35

+1.6%↑

AXB

60.3

+0.84%↑

JPM

294.13

+1.77%↑

BAC

45.83

+0.48%↑

WFC

77.54

-0.32%↓

MS

141.35

+1.6%↑

AXB

60.3

+0.84%↑

JPM

294.13

+1.77%↑

BAC

45.83

+0.48%↑

WFC

77.54

-0.32%↓

MS

141.35

+1.6%↑

Search

TPG Specialty Lending Inc

Closed

SectorFinance

23.75 -0.63

Overview

Share price change

24h

Current

Min

23.69

Max

24.03

Key metrics

By Trading Economics

Income

-14M

37M

Sales

49M

114M

P/E

Sector Avg

12.693

25.916

Dividend yield

8.51

Profit margin

32.44

EBITDA

-17M

64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+0.96% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

8.51%

3.70%

Next Dividend date

29 Sept 2025

Next Ex Dividend date

15 Sept 2025

Market Stats

By TradingEconomics

Market Cap

279M

2.3B

Previous open

24.38

Previous close

23.75

News Sentiment

By Acuity

20%

80%

29 / 536 Finance

Technical Score

By Trading Central

Confidence

Bearish Evidence

TPG Specialty Lending Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

TPG Specialty Lending Inc Forecast

Price Target

By TipRanks

0.96% upside

12 Months Forecast

Average 24.14 USD  0.96%

High 25 USD

Low 23 USD

Based on 7 Wall Street analysts offering 12 month price targets forTPG Specialty Lending Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

20.83 / 21.65Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

29 / 536 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TPG Specialty Lending Inc

Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.